The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas

International Journal of Surgical Oncology

Volumn 2013, Issue , 2013, Pages

  Mirza, A ^a   Pritchard, S ^a   Welch, I ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFECT; ESOPHAGUS TUMOR; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RISK FACTOR; STOMACH TUMOR; TUMOR RECURRENCE; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; PROCEDURES; STOMACH NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84885573151     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2013/781742     Document Type: Article

References (34)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D. M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010 127 12 2893 2917 2-s2.0-78049485263 10.1002/ijc.25516
2. CRC U. Cancer Research UK, Cancer Stats-Key Facts 2009 London, UK
3. Dolan K., Sutton R., Walker S. J., Morris A., Campbell F., Williams E. M., New classification of oesophageal and gastric carcinomas derived from changinq patterns in epidemiology. British Journal of Cancer 1999 80 5-6 834 842 2-s2.0-0032920762 10.1038/sj.bjc.6690429 (Pubitemid 29209848)
4. Chang J. T., Katzka D. A., Gastroesophageal reflux disease, barrett esophagus, and esophageal adenocarcinoma. Archives of Internal Medicine 2004 164 14 1482 1488 2-s2.0-3242806675 10.1001/archinte.164.14.1482 (Pubitemid 38970466)
5. Ryan A. M., Duong M., Healy L., Ryan S. A., Parekh N., Reynolds J. V., Power D. G., Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiology 2011 35 4 309 319 2-s2.0-79960616415 10.1016/j.canep.2011.03.001
6. van Cutsem E., Dicato M., Geva R., Arber N., Bang Y., Benson A., Cervantes A., Diaz-Rubio E., Ducreux M., Glynne-Jones R., Grothey A., Haller D., Haustermans K., Kerr D., Nordlinger B., Marshall J., Minsky B. D., Kang Y. K., Labianca R., Lordick F., Ohtsu A., Pavlidis N., Roth A., Rougier P., Schmoll H. J., Sobrero A., Tabernero J., van de Velde C., Zalcberg J., The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Annals of Oncology 2011 22 5 1 9 2-s2.0-79958106046 10.1093/annonc/mdr284
7. Reid T. D., Sanyaolu L. N., Chan D., Williams G. T., Lewis W. G., Relative prognostic value of TNM7 vs. TNM6 in staging oesophageal cancer. British Journal of Cancer 2011 105 6 842 846 2-s2.0-80052436842 10.1038/bjc.2011.320
8. Kayani B., Zacharakis E., Ahmed K., Hanna G. B., Lymph node metastases and prognosis in oesophageal carcinoma-A systematic review. European Journal of Surgical Oncology 2011 37 9 747 753 2-s2.0-80051653058 10.1016/j.ejso.2011.06. 018
9. Sano T., Adjuvant and neoadjuvant therapy of gastric cancer: a comparison of three pivotal studies. Current Oncology Reports 2008 10 3 191 198 2-s2.0-58149125903 10.1007/s11912-008-0030-y
10. Macdonald J. S., Smalley S. R., Benedetti J., Hundahl S. A., Estes N. C., Stemmermann G. N., Haller D. G., Ajani J. A., Gunderson L. L., Milburn Jessup J., Martenson J. A., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 2001 345 10 725 730 2-s2.0-0035818048 10.1056/NEJMoa010187
11. Fuchs C., Tepper J. E., Niedzwiecki D., Hollis D., Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101. Journal of Clinical Oncology 2011 29 supplement, abstract 4003
12. Stahl M., Walz M. K., Stuschke M., Lehmann N., Meyer H.-J., Riera-Knorrenschild J., Langer P., Engenhart-Cabillic R., Bitzer M., Königsrainer A., Budach W., Wilke H., Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology 2009 27 6 851 856 2-s2.0-60849118127 10.1200/JCO.2008.17.0506
13. Jansen E., Randomized phase III trial of adjuvant cehmotherapy or chemo-radiotherapy in resectable gastric cancer (CRITICS). 2008
14. Boige V., Pignon J., Saint-Aubert B., Lasser P., Conroy T., Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Journal of Clinical Oncology 2007 25 supplement, abstract 4510 18
15. Cunningham D., Allum W. H., Stenning S. P., Thompson J. N., Van De Velde C. J. H., Nicolson M., Scarffe J. H., Lofts F. J., Falk S. J., Iveson T. J., Smith D. B., Langley R. E., Verma M., Weeden S., Yu J. C., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2006 355 1 11 20 2-s2.0-33745726677 10.1056/NEJMoa055531
16. Fujimoto S., Watanabe Y., Enomoto K., Adachi M., Itoh K., Studies on preoperative cancer chemotherapy. Methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine. Cancer 1969 24 3 433 441 2-s2.0-0014573801
17. Fujimoto S., Akao T., Itoh B., A study of survival in patients with stomach cancer treated by a combination of preoperative intra arterial infusion therapy and surgery. Cancer 1976 37 4 1648 1653 2-s2.0-0017084317
18. Hartgrink H. H., van de Velde C. J. H., Putter H., Songun I., Tesselaar M. E. T., Kranenbarg E. K., de Vries J. E., Wils J. A., van der Bijl J., van Krieken J. H. J. M., Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology 2004 30 6 643 649 2-s2.0-4043161470 10.1016/j.ejso.2004.04.013 (Pubitemid 39060735)
19. Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., Furukawa H., Nakajima T., Ohashi Y., Imamura H., Higashino M., Yamamura Y., Kurita A., Arai K., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New England Journal of Medicine 2007 357 18 1810 1820 2-s2.0-35748946650 10.1056/NEJMoa072252 (Pubitemid 350044801)
20. Paoletti X., Oba K., Burzykowski T., Michiels S., Ohashi Y., Pignon J.-P., Rougier P., Sakamoto J., Sargent D., Sasako M., Van Cutsem E., Buyse M., Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Journal of the American Medical Association 2010 303 17 1729 1737 2-s2.0-77951902722 10.1001/jama.2010.534
21. Chang H. M., Jung K. H., Kim T.-Y., Kim W. S., Yang H.-K., Lee K. U., Choe K. J., Heo D. S., Bang Y.-J., Kim N. K., A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Annals of Oncology 2002 13 11 1779 1785 2-s2.0-0036860299 10.1093/annonc/mdf302 (Pubitemid 35439458)
22. Karacetin D., Incekara O., A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas. Journal of Balkan Union of Oncology 2004 9 3 263 267 2-s2.0-14944350273 (Pubitemid 40360801)
23. Cascinu S., Labianca R., Barone C., Santoro A., Carnaghi C., Cassano A., Beretta G. D., Catalano V., Bertetto O., Barni S., Frontini L., Aitini E., Rota S., Torri V., Floriani I., Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. Journal of the National Cancer Institute 2007 99 8 601 607 2-s2.0-34247582754 10.1093/jnci/djk131 (Pubitemid 47073541)
24. Di Bartolomeo M., Buzzoni R., Mariani L., Ferrario E., Katia D., Gevorgyan A., Zilembo N., Bordonaro R., Bochicchio A. M., Massidda B., Ardizzoni A., Marini G., Aitini E., Schieppati G., Comella G., Pinotti G., Palazzo S., Cicero G., Bajetta E., Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma: a randomized phase III trial. Oncology 2007 71 5-6 341 346 2-s2.0-35348838642 10.1159/000108575 (Pubitemid 47573695)
25. Kang Y., Chang H., Min Y., Zang D., A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (AMC 0201). Journal of Clinical Oncology 2008 26 supplement, abstract 453
26. Tsuburaya A., Sakamoto J., Morita S., Kodera Y., Kobayashi M., Miyashita Y., Macdonald J. S., A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the stomach cancer adjuvant multi-institutional trial group (Samit) trial. Japanese Journal of Clinical Oncology 2005 35 11 672 675 2-s2.0-30444452979 10.1093/jjco/hyi179 (Pubitemid 43071446)
27. Kobayashi M., Tsuburaya A., Yoshida K., Adjuvant paclitaxel followed by oral fluoropyrimidines for gastric cancer: safety data of the factorial phase III SAMIT trial. Journal of Clinical Oncology 2012 supplement 4
28. Bang Y.-J., Kim Y.-W., Yang H.-K., Chung H. C., Park Y.-K., Lee K. H., Lee K.-W., Kim Y. H., Noh S.-I., Cho J. Y., Mok Y. J., Kim Y. H., Ji J., Yeh T.-S., Button P., Sirzén F., Noh S. H., Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet 2012 379 9813 315 321 2-s2.0-84856382467 10.1016/S0140-6736(11)61873-4
29. Macdonald J. S., Benedetti J., Smalley S., Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). Journal of Clinical Oncology 2009 27 supplement, abstract 4515 15
30. Dikken J. L., van Sandick J. W., Maurits Swellengrebel H., Lind P. A., Putter H., Jansen E. P. M., Boot H., van Grieken N. C. T., van de Velde C. J. H., Verheij M., Cats A., Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011 11, article 329 2-s2.0-79960892052 10.1186/1471-2407-11-329
31. Bamias A., Karina M., Papakostas P., Kostopoulos I., Bobos M., Vourli G., Samantas E., Christodoulou C., Pentheroudakis G., Pectasides D., Dimopoulos M. A., Fountzilas G., A randomized phase iii study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology 2010 65 6 1009 1021 2-s2.0-77951885560 10.1007/s00280-010-1256-6
32. Fiorica F., Cartei F., Enea M., Licata A., Cabibbo G., Carau B., Liboni A., Ursino S., Cammà C., The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treatment Reviews 2007 33 8 729 740 2-s2.0-36049026194 10.1016/j.ctrv.2007.08. 005 (Pubitemid 350082668)
33. Li W., Qin J., Sun Y.-H., Liu T.-S., Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World Journal of Gastroenterology 2010 16 44 5621 5628 2-s2.0-78649715222 10.3748/wjg.v16.i44.5621
34. Smyth E., Langley R., Stenning S., Stevenson L., ST03: a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, oesophagogastric junction (OGJ) or lower oesophageal adenocarcinoma. Journal of Clinical Oncology 2012 30